CS
SMMT icon

Credit Suisse’s Summit Therapeutics SMMT Stock Holding History

Credit Suisse’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$460K Buy
111,078
+2,728
+3% +$10.8K ﹤0.01% 2669
2023
Q4 		$283K Sell
108,350
-3,272
-3% -$6.73K ﹤0.01% 2927
2023
Q3 		$209K Sell
111,622
-7,456
-6% -$14.2K ﹤0.01% 3021
2023
Q2 		$299K Buy
+119,078
New +$217K ﹤0.01% 3004
2022
Q3 		– Sell
-14
Closed – – 4262
2022
Q2 		$0 Buy
+14
New +$20 ﹤0.01% 4278

Other funds holding SMMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Credit Suisse's SMMT Position: Q1 2024 in Review

Credit Suisse increased its Summit Therapeutics (SMMT) stake by 2.5% in Q1 2024, buying an estimated $10.8K and bringing the position to 111,078 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #2669.

Credit Suisse first reported a position in SMMT in Q2 2022 and has held it in 5 quarters since. 105 funds tracked by Wall St. Rank hold SMMT as of Q1 2024.

  • Credit Suisse held 111,078 shares of Summit Therapeutics worth $460K as of Q1 2024.
  • Credit Suisse bought 2,728 Summit Therapeutics shares in Q1 2024, an estimated $10.8K.
  • Summit Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2669 holding.
  • Credit Suisse first reported a position in Summit Therapeutics in Q2 2022 and has held it in 5 quarters since.
  • 105 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.